Tag: Policy + Advocacy Updates

Weekly Policy Blog: Join CBSA in Asking Congress to Address the R&D Tax Now 

By: Colorado BioScience Association   Date: 11/13/2023

Join CBSA in asking Congress to support leading-edge health innovation by American life sciences companies. We are asking Congress to remove a “tax on innovation” by restoring the immediate expensing...

Learn More

Weekly Policy Blog: Opposition to CMS’ Proposed Medicaid Drug Rebate Program (MDRP) Rule

By: Colorado BioScience Association   Date: 11/06/2023

CBSA and other members of the Council of State Bioscience Associations (CSBA) have submitted a letter to the Centers for Medicare & Medicaid Services (CMS) expressing our deep concern with a recen...

Learn More

Weekly Policy Blog: CBSA Has Concerns About Inconsistency of Preliminary Data Review Process for Drugs Under Affordability Review by PDAB 

By: Colorado BioScience Association   Date: 10/30/2023

CBSA has serious concerns about the Colorado Prescription Drug Affordability Board’s inconsistent approach to the preliminary data review process for drugs under affordability review in the first coho...

Learn More

Weekly Policy Blog: USITC Report Released on TRIPS COVID-19 IP Waiver Expansion

By: Colorado BioScience Association   Date: 10/23/2023

In June 2022, World Trade Organization (WTO) member states agreed to waive certain WTO intellectual property protections for COVID-19 vaccines. The U.S. Trade Representative (USTR) has been considerin...

Learn More

Weekly Policy Blog: CBSA Co-Hosts Facility Tours for State Legislators and Local Leaders 

By: Colorado BioScience Association   Date: 10/16/2023

Weekly Policy Blog: CBSA Co-Hosts Facility Tours for State Legislators and Local Leaders  This month CBSA partnered with both Terumo Blood and Cell Technologies (Terumo BCT) and AGC Biologics to host...

Learn More

Weekly Policy Blog: CBSA Urges Congress to Pass the PASTEUR Act 

By: Colorado BioScience Association   Date: 09/25/2023

Earlier this month, CBSA participated in PASTEUR Advocacy Day, joining Biotechnology Innovation Organization (BIO) and other organizations, including Infectious Diseases Society of America, Cystic Fib...

Learn More

Efforts to Control Prescription Drug Pricing Harm Collaborative Work to Advance Patient Care with Health Innovations

By: Colorado BioScience Association   Date: 09/18/2023

Elyse Blazevich, President & CEO, Colorado BioScience Association Colorado’s life sciences community and our state leaders share an unwavering commitment to improving patient lives and making sure...

Learn More

Weekly Policy Blog: FDA Guidances on 510(k) Submissions; Actuarial Review of Biomarker Testing Coverage Bill 

By: Colorado BioScience Association   Date: 09/11/2023

FDA Issues Three Guidances on Premarket Notification [510(k)] Program  On September 7, 2023, the U.S. Food and Drug Administration’s (FDA’s) Center for Devices and Radiological Health (CDRH) issu...

Learn More

Weekly Policy Blog: CMS Announces Drugs Subject to Price Controls Under the IRA 

By: Colorado BioScience Association   Date: 09/05/2023

On August 29, 2023, the Centers for Medicare and Medicaid Services (CMS) announced the first ten prescription drugs that will be subject to price controls in Medicare under the Inflation Reduction Act...

Learn More

Weekly Policy Blog: CBSA and Partners Provide Recommendations to Improve CMS’ Transitional Coverage for Emerging Technologies (TCET) Proposal 

By: Colorado BioScience Association   Date: 08/28/2023

CBSA advocates for policies that improve patient access to life-saving novel technologies. This week, CBSA signed on to a letter responding to the long-awaited proposed Transitional Coverage for Emerg...

Learn More